US loss of exclusivity · Oncology

Imbruvica

AbbVie / Johnson & Johnson

2032US generics from
2025Today: 20262037
2025 worldwide sales
$4.0B
Date basis
Settlement / court date
US generics
Approved, waiting to launch
Medicare price
−38% from 2026
Pharma Patent Cliff by readouts.io Data checked 24 October 2026 · Full Imbruvica timeline →